BRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017

Mon Jun 6, 2016 5:08pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

June 6 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting

* Phase III trial for endometrial cancer expected to be completed in Q3 2016

* To file a new drug application for zoptrex in first half of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)